AB 1842 (Reyes, D-San Bernardino)

AB 1842 requires a group or individual health care service plan or health insurer offering an outpatient prescription drug benefit to provide coverage without prior authorization, step therapy, or utilization review for at least one medication approved by the United States Food and Drug Administration in each of four designated categories, including medication for the reversal of opioid overdose, such as a naloxone product or another opioid antagonist.